Metabolic reprogramming in cancer is not only a biological hallmark but also reveals
treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment …

Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …

The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …

Regular physical activity is associated with lower cancer incidence and mortality, as well as
with a lower rate of tumour recurrence. The epidemiological evidence is supported by …

The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …

Physical exercise has gradually become a focus in cancer treatment due to its pronounced
role in reducing cancer risk, enhancing therapeutic efficacy, and improving prognosis. In …

Cytokine therapy mediates the interaction between immune cells and non‐immune cells in
the tumor microenvironment (TME), forming a promising approach in cancer therapy …

Physical activity reduces cancer-associated mortality through multiple mechanisms,
including tumor immune microenvironment (TIME) reprogramming. However, whether and …

Pancreatic cancer is an aggressive cancer with a poor prognosis. Metabolic abnormalities
are one of the hallmarks of pancreatic cancer, and pancreatic cancer cells can adapt to …

Interleukin-15 (IL-15) is a cytokine that belongs to the interleukin-2 (IL-2) family and is
essential for the development, proliferation, and activation of immune cells, including natural …